Canaccord Genuity Maintains Buy on Harpoon Therapeutics, Lowers Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst William Maughan maintains a 'Buy' rating on Harpoon Therapeutics (NASDAQ:HARP) but has lowered the price target from $80 to $40.
September 14, 2023 | 3:15 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Harpoon Therapeutics' price target has been lowered from $80 to $40 by Canaccord Genuity, though the 'Buy' rating is maintained.
The news directly pertains to Harpoon Therapeutics as the company's price target has been lowered by Canaccord Genuity. However, the 'Buy' rating is maintained which indicates that the analyst still sees potential in the stock. This could lead to mixed reactions in the market, hence the neutral score.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100